# Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome

> **NCT05137496** · PHASE3 · UNKNOWN · sponsor: **Beijing Friendship Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Macrophage Activation Syndrome

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** methylprednisolone

## Key facts

- **NCT ID:** NCT05137496
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-01
- **Primary completion:** 2023-06-01
- **Final completion:** 2024-06-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05137496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05137496, "Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05137496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*